Pure Global
NCT05192603

Comparison Between Low FODMAP and SSRD in IBS

Comparison in the Effects and Mechanisms Between Low Fermentable-, Oligo-, di-, and Monosaccharides and Polyols (FODMAP) and Starch- and Sucrose-reduced Diet (SSRD) in Irritable Bowel Syndrome (IBS)
Region Skane·ClinicalTrials.gov·dietary supplementEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
IBS - Irritable Bowel Syndrome
Drug/Device/Intervention
low FODMAP or SSRD
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
Region Skane
Location
Malmö, Sweden
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2022
End date
Mar 31, 2029
Enrollment
200 participants
Primary outcome

Efficiency on bowel and extra-intestinal symptoms,Efficiency on bowel and extra-intestinal symptoms,Efficiency on bowel symptoms,Efficiency on bowel symptoms

Summary

The aim of the present study is to compare the efficiency of low FODMAP and SSRD to reduce
 symptoms in IBS, and to study the mechanisms and consequences of the two diets.

ICD-10 classifications
Irritable bowel syndrome with predominant constipation [IBS-C]Irritable bowel syndromeIrritable bowel syndrome with predominant diarrhoea [IBS-D]Irritable bowel syndrome with mixed bowel habits [IBS-M]Other and unspecified irritable bowel syndrome
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05192603
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05192603 through Pure Global AI's free database. This phase not specified trial is sponsored by Region Skane and is currently Enrolling by invitation. The study focuses on IBS - Irritable Bowel Syndrome. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.